In conclusion, we identify the PDGFRβ/STAT5 axis acts as a booster of malignancy, operating in parallel to the oncogenic NPM-ALK-STAT3 signaling cascade, resulting in a more aggressive ALCL disease entity. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.